Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
PITTSBURGH, August 19, 2026--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the closing of a $14 million extension of its Series A financing. The financing was led by Company K Partners, with participation from SV Investment, Flexus Partners, as well as continued support from existing investors including affiliates of Nextrans and Quad Investment Management.
CarbonSix,Inc., a pioneer in Physical AI for the manufacturing sector, announced today that it has raised $40 million (approx. KRW 60 billion) in a Series A funding round from a syndicate of premier U.S. and South Korean venture capital firms.
The Series B funding will back global deployment, product development and partnerships for AI-focused computational memory solutions.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.